We anticipate the significant progress of the pipeline to continue, including our Immuno-Oncology and targeted treatments. We will also maintain our commitment to drive efficiency across the company to support our efforts to bring new medicines to patients.
AstraZeneca Q1 2017 Results media conference
Thursday 27th April 2017 9:00am UK time
Media are invited to join the Q1 2017 Results media conference hosted by Pascal Soriot, CEO.
Latest press releases
Q1 2017 Results
Tagrisso receives full approval in the EU
AstraZeneca marks a key milestone with the ‘topping out’ of new global R&D centre and HQ in Cambridge, UK
Tagrisso (osimertinib) receives US FDA full approval
AstraZeneca’s potential medicine for neuromyelitis optica spectrum disorder receives orphan designation in Europe
These press releases are specifically for health specialist/medical media and are not for consumer press.